BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference
The following press release was obtained fromΒ BridgeBio.com, parent company ofΒ QED therapeutics. To learn more about QED and their research surrounding achondroplasia and other skeletal dysplasias,Β click here. PALO ALTO, Calif., June…